Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the bodyâs remarkable capacity for cellular growth and repair. Our approach to drug discovery is driven by deep scientific expertiseâand an urgency to deliver effective treatments to thousands of patients who have few or no therapeutic options. The Companyâs lead product candidate, luspatercept, is a first-in-class erythroid (red blood cell) maturation agent (EMA) being developed to treat patients who have serious blood disorders marked by a late-stage defect in the maturation of red blood cells. Alongside our partner Celgeneâa leader in hematologyâwe are advancing multiple Phase 2 and Phase 3 trials of luspatercept in five target indications across myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. Acceleron is also advancing a neuromuscular program with a locally-acting âMyostatin+â agent, ACE-083. We recently initiated a Phase 2 trial of sotatercept in pulmonary arterial hypertension (PAH). Acceleron has ongoing preclinical research efforts targeting additional indications in these three disease areas in which there is high unmet medical need. Source
No articles found.
SI-BONE is a medical device company that has pioneered a proprietary minimally inv...
SI-BONE is a medical device company that has pi...
Founded in 2015 and based in Los Angeles, California. Magnabid.com is a trusted me...
Founded in 2015 and based in Los Angeles, Calif...
Quidel Corporation (Nasdaq: QDEL) is a California-based leading manufacturer of di...
Quidel Corporation (Nasdaq: QDEL) is a Californ...
Mereo BioPharma is a biopharmaceutical company focused on the development and comm...
Mereo BioPharma is a biopharmaceutical company ...
Join the National Investor Network and get the latest information with your interests in mind.